These observations have at least two important implications: first, FOXA2 is not the only factor that can promote metastatic competency in SCLC; and second, additional regulatory mechanisms beyond ASCL1 must control whether or not FOXA2 is expressed. Here, FOXA2 is linked to small cell lung carcinoma.